Etoposide (VP-16) in the treatment of lung cancer
- 31 December 1983
- journal article
- review article
- Published by Elsevier BV in Cancer Treatment Reviews
- Vol. 10 (4), 245-264
- https://doi.org/10.1016/0305-7372(83)90013-0
Abstract
No abstract availableThis publication has 18 references indexed in Scilit:
- Cisplatin, adriamycin, and etoposide (cav) for remission induction of small-cell bronchogenic carcinoma. Evaluation of efficacy and toxicity and pilot study of a “late intensification” with autologous bone-marrow rescueCancer, 1982
- Etoposide after ACO treatment for small-cell bronchogenic carcinomaCancer Treatment Reviews, 1982
- Combination cis-platinum and etoposide in small-cell lung cancerCancer Treatment Reviews, 1982
- Phase III study of CCNU, cyclophosphamide, adriamycin, vincristine, and VP-16 in small-cell carcinoma of the lungCancer, 1982
- Treatment of small cell lung cancer with a combination of VP16-213 and cyclophosphamide with cisplatin or radiotherapyCancer Chemotherapy and Pharmacology, 1982
- Pharmacokinetics of VP16-213 given by different administration methodsCancer Chemotherapy and Pharmacology, 1982
- The clinical pharmacology of VM26 and VP16-213Cancer Chemotherapy and Pharmacology, 1982
- Chemotherapy of small cell carcinoma of the lung with V. P. 16–213Cancer, 1978
- Treatment of small cell anaplastic carcinoma of the lung with the oral solution of VP-16-213 (NSC 141540, 4′-demethylepipodophyllotoxin 9-(4,6-0-ethylidene-β-D-glucopyranoside)Cancer, 1977
- Combination chemotherapy with 4′Demethylepipodophyllotoxin 9-(4,6-0-ethylidene-β-d-glucopyranoside), VP 16–213 (NSC 141540) in L1210 LeukemiaEuropean Journal of Cancer (1965), 1976